Leerink Partners analyst Mani Foroohar has maintained their bullish stance on RGNX stock, giving a Buy rating on March 14.
Mani Foroohar’s rating is based on a combination of factors that highlight RegenXBio’s promising pipeline and strategic partnerships. The company’s pivotal trial for RGX-202 in Duchenne muscular dystrophy is progressing well, with nearly half of the enrollment completed and expectations for accelerated enrollment due to additional functional data and new site activations. This trial is expected to complete enrollment by mid-2025, with topline data anticipated in the first half of 2026, and a BLA submission under accelerated approval by mid-2026.
Additionally, RegenXBio’s collaboration with ABBV for the development of surabgene lomparvovec in wet age-related macular degeneration and diabetic retinopathy is advancing, with pivotal data expected in 2026. The partnership with Nippon Shinyaku for RGX-121 and RGX-111, along with the completion of the BLA submission for RGX-121, positions the company for potential approval in the second half of 2025. Furthermore, the company has a solid financial outlook with a cash runway extending to the second half of 2026 and several non-dilutive capital sources, including milestone payments and royalty streams, enhancing its financial stability.
In another report released on March 14, Morgan Stanley also maintained a Buy rating on the stock with a $24.00 price target.